US6255059B1
(en)
|
1993-03-31 |
2001-07-03 |
Cadus Pharmaceutical Corporation |
Methods for identifying G protein coupled receptor effectors
|
US5876951A
(en)
*
|
1993-03-31 |
1999-03-02 |
Cadus Pharmaceutical Corporation |
Yeast cells engineered to produce pheromone system protein surrogates and uses therefor
|
US7416881B1
(en)
|
1993-03-31 |
2008-08-26 |
Cadus Technologies, Inc. |
Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
|
US6100042A
(en)
*
|
1993-03-31 |
2000-08-08 |
Cadus Pharmaceutical Corporation |
Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
|
US20030054402A1
(en)
*
|
1993-03-31 |
2003-03-20 |
Cadus Pharmaceutical Corporation |
Methods and compositions for identifying receptor effectors
|
US5789184A
(en)
*
|
1993-03-31 |
1998-08-04 |
Cadus Pharmaceutical Corporation |
Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
|
US7235648B1
(en)
|
1993-03-31 |
2007-06-26 |
Cadus Technologies, Inc. |
Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
|
US6864060B1
(en)
|
1993-03-31 |
2005-03-08 |
Cadus Technologies, Inc. |
Yeast cells expressing modified G proteins and methods of use therefor
|
US6150137A
(en)
*
|
1994-05-27 |
2000-11-21 |
Ariad Pharmaceuticals, Inc. |
Immunosuppressant target proteins
|
US5989808A
(en)
*
|
1994-06-14 |
1999-11-23 |
American Cyanamid Company |
Identification of compounds affecting specific interaction of peptide binding pairs
|
US5695941A
(en)
*
|
1994-06-22 |
1997-12-09 |
The General Hospital Corporation |
Interaction trap systems for analysis of protein networks
|
US6576236B1
(en)
|
1994-07-01 |
2003-06-10 |
Dana Farber Cancer Institute |
Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
|
DE69532127T2
(de)
*
|
1994-07-20 |
2004-08-26 |
Genetics Institute, Inc., Cambridge |
Interaktions-fullensysteme zum nachweis von protein-interaktionen
|
US6399296B1
(en)
|
1994-07-20 |
2002-06-04 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
WO1996003501A1
(en)
*
|
1994-07-22 |
1996-02-08 |
Ciba-Geigy Ag |
Dual hybrid system
|
DE69636866D1
(en)
|
1995-04-11 |
2007-03-15 |
Gen Hospital Corp |
Reverse "two-hybrid"-systeme
|
US5637463A
(en)
*
|
1995-05-04 |
1997-06-10 |
Hoffmann-La Roche Inc. |
Method to detect protein-protein interactions
|
US5821048B1
(en)
*
|
1995-06-07 |
2000-05-23 |
Harvard College |
Methods kits and compositions for diagnosing papillomavirus infection
|
US5968802A
(en)
*
|
1995-06-07 |
1999-10-19 |
Wang; Bruce |
Nuclear cyclophilin
|
US20030215798A1
(en)
*
|
1997-06-16 |
2003-11-20 |
Diversa Corporation |
High throughput fluorescence-based screening for novel enzymes
|
EP0790304A1
(de)
*
|
1995-12-21 |
1997-08-20 |
AMERSHAM INTERNATIONAL plc |
Auf Nachweismethoden bezogene Verbesserungen
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
WO1997044447A2
(en)
*
|
1996-05-03 |
1997-11-27 |
President And Fellows Of Harvard College |
Transcriptional activation system, activators, and uses therefor
|
US6083693A
(en)
*
|
1996-06-14 |
2000-07-04 |
Curagen Corporation |
Identification and comparison of protein-protein interactions that occur in populations
|
US5807708A
(en)
*
|
1996-07-30 |
1998-09-15 |
Millennium Pharmaceuticals, Inc. |
Conservin nucleic acid molecules and compositions
|
US5925523A
(en)
|
1996-08-23 |
1999-07-20 |
President & Fellows Of Harvard College |
Intraction trap assay, reagents and uses thereof
|
WO1998007845A1
(en)
*
|
1996-08-23 |
1998-02-26 |
President And Fellows Of Harvard College |
Interaction trap assay, reagents and uses thereof
|
EP0929691B1
(de)
*
|
1996-09-24 |
2004-12-15 |
Cadus Pharmaceutical Corporation |
Verfahren und zusammensetzungen für die identifizierung von receptor effectoren
|
AU4903897A
(en)
*
|
1996-10-16 |
1998-05-11 |
Bittech, Inc. |
Phenotypic assays of cyclin/cyclin-dependent kinase function
|
US6048693A
(en)
*
|
1996-10-16 |
2000-04-11 |
Bittech, Inc. |
Phenotypic assays of cyclin/cyclin-dependent kinase function
|
US20020137890A1
(en)
*
|
1997-03-31 |
2002-09-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
DE69842225D1
(de)
|
1997-04-16 |
2011-05-26 |
Millennium Pharm Inc |
Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
|
US6426411B1
(en)
|
1997-05-30 |
2002-07-30 |
Dana-Farber Cancer Institute |
PGC-1, a novel brown fat pparγ coactivator
|
US5885779A
(en)
*
|
1997-09-09 |
1999-03-23 |
University Of British Columbia |
Repressed trans-activator system for characterization of protein-protein interactions
|
US6344554B1
(en)
|
1997-10-02 |
2002-02-05 |
Regents Of The University Of California |
Polynucleotide sequences from Candida albicans encoding polypeptides associated with filamentous growth
|
US6332897B1
(en)
*
|
1998-03-27 |
2001-12-25 |
Glaxo Wellcome Inc. |
Assay methods
|
US6355473B1
(en)
|
1998-05-06 |
2002-03-12 |
Cadus Pharmaceutical Corp. |
Yeast cells having mutations in stp22 and uses therefor
|
US6733991B1
(en)
|
1998-05-08 |
2004-05-11 |
Osi Pharmaceuticals, Inc. |
AGS proteins and nucleic acid molecules and uses therefor
|
US6746852B1
(en)
|
1998-05-08 |
2004-06-08 |
Osi Pharmaceuticals, Inc. |
AGS proteins and nucleic acid molecules and uses thereof
|
CA2256121A1
(en)
*
|
1998-06-08 |
1999-12-08 |
Hong Wang |
Cyclin-dependent kinase inhibitors as plant growth regulators
|
US7273747B2
(en)
*
|
1998-08-27 |
2007-09-25 |
Cadus Technologies, Inc. |
Cell having amplified signal transduction pathway responses and uses therefor
|
US6251605B1
(en)
|
1998-10-27 |
2001-06-26 |
Cadus Pharmaceutical Corporation |
Yeast cells having mutations in Cav1 and uses therefor
|
AU2030000A
(en)
*
|
1998-11-25 |
2000-06-13 |
Cadus Pharmaceutical Corporation |
Methods and compositions for identifying receptor effectors
|
US6504008B1
(en)
|
1999-02-01 |
2003-01-07 |
Cadus Technologies, Inc. |
Cell based signal generation
|
EP2301947A3
(de)
|
1999-02-26 |
2011-11-23 |
Millennium Pharmaceuticals, Inc. |
Sekretierte Proteine und Verwendungen dafür
|
CA2362414A1
(en)
|
1999-03-12 |
2000-09-14 |
Gpc Biotech, Inc. |
Methods and reagents for identifying synthetic genetic elements
|
US7396905B1
(en)
|
1999-05-21 |
2008-07-08 |
Mckeon Frank |
Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
|
US6555325B1
(en)
|
1999-06-14 |
2003-04-29 |
Cadus Technologies, Inc. |
System for detection of a functional interaction between a compound and a cellular signal transduction component
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
PT1210428E
(pt)
|
1999-08-23 |
2015-07-21 |
Genetics Inst Llc |
Pd-1, um recetor para b7-4 e suas utilizações
|
US7223533B2
(en)
|
1999-09-10 |
2007-05-29 |
Cadus Technologies, Inc. |
Cell surface proteins and use thereof as indicators of activation of cellular signal transduction pathways
|
US20020061512A1
(en)
*
|
2000-02-18 |
2002-05-23 |
Kim Jin-Soo |
Zinc finger domains and methods of identifying same
|
EP2143796A3
(de)
|
2000-02-29 |
2010-03-17 |
Millennium Pharmaceuticals, Inc. |
1983-, 52881-, 2398-, 45449-, 50289- und 52872-G- Protein-gekoppelte Rezeptoren und Verwendungen davon
|
US20030129724A1
(en)
|
2000-03-03 |
2003-07-10 |
Grozinger Christina M. |
Class II human histone deacetylases, and uses related thereto
|
US7029847B2
(en)
*
|
2000-05-16 |
2006-04-18 |
Massachusetts Institute Of Technology |
Methods and compositions for interaction trap assays
|
US20030044787A1
(en)
*
|
2000-05-16 |
2003-03-06 |
Joung J. Keith |
Methods and compositions for interaction trap assays
|
EP1290192A2
(de)
|
2000-05-30 |
2003-03-12 |
Bayer Aktiengesellschaft |
Regulation der humanen plc delta-1
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
CA2436805A1
(en)
|
2000-11-07 |
2002-10-17 |
Pioneer Hi-Bred International, Inc. |
Cell cycle nucleic acids, polypeptides and uses thereof
|
WO2002046434A2
(en)
*
|
2000-12-08 |
2002-06-13 |
Alexion Pharmaceuticals, Inc. |
Plasmid vectors
|
WO2002070678A2
(en)
|
2001-02-05 |
2002-09-12 |
Bayer Aktiengesellschaft |
Regulation of human serine/threonine protein kinase
|
EP1370678A4
(de)
*
|
2001-03-02 |
2005-09-07 |
Mds Proteomics Inc |
Verfahren und reagenzien zur apoptoseregulation
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2442066C
(en)
|
2001-04-02 |
2005-11-01 |
Wyeth |
Pd-1, a receptor for b7-4, and uses therefor
|
WO2002083855A2
(en)
|
2001-04-16 |
2002-10-24 |
Wyeth Holdings Corporation |
Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
|
US7244853B2
(en)
|
2001-05-09 |
2007-07-17 |
President And Fellows Of Harvard College |
Dioxanes and uses thereof
|
NZ560643A
(en)
|
2001-05-31 |
2009-03-31 |
Performance Plants Inc |
Compositions and methods of increasing stress tolerance in plants
|
CA2652991A1
(en)
|
2001-07-16 |
2003-11-13 |
Caprotec Bioanalytics Gmbh |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
US7229774B2
(en)
|
2001-08-02 |
2007-06-12 |
Regents Of The University Of Michigan |
Expression profile of prostate cancer
|
CA2457095A1
(en)
*
|
2001-08-17 |
2003-02-27 |
Toolgen, Inc. |
Zinc finger domain libraries
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
EP1525323B1
(de)
|
2001-11-09 |
2015-01-21 |
Dana-Farber Cancer Institute, Inc. |
Pgc-1beta, ein neues pgc-1-homolog, und verwendungen dafür
|
ES2337989T3
(es)
|
2001-12-18 |
2010-05-03 |
Endocube Sas |
Nuevas proteinas asociadas a la muerte de la familia thap y rutas par4 relacionadas implicadas en el control de la apoptosis.
|
US7858297B2
(en)
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
EP1455815A4
(de)
|
2001-12-19 |
2006-11-02 |
Millennium Pharm Inc |
Mitglieder der familie der humanen diacylglycerol-acyltransferase 2 (dgat2) und ihre verwendung
|
EP1463807A4
(de)
|
2001-12-19 |
2006-04-12 |
Bristol Myers Squibb Co |
Formiatdehydrogenase aus pichia pastoris und verwendungen dafür
|
WO2003057916A2
(en)
|
2002-01-09 |
2003-07-17 |
Riken |
Cancer profiles
|
US20020094519A1
(en)
*
|
2002-03-07 |
2002-07-18 |
Agencourt Bioscience Corporation |
Detection of protein interactions
|
DE60325847D1
(de)
*
|
2002-03-11 |
2009-03-05 |
Caprotec Bioanalytics Gmbh |
Verbindungen und verfahren für die analyse des proteoms
|
US20040116658A1
(en)
*
|
2002-03-22 |
2004-06-17 |
Ken-Shwo Dai |
Human KAP/Cdi1-related gene variant associated with small cell lung cancer
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
EP1900827A3
(de)
|
2002-05-21 |
2008-04-16 |
Bayer HealthCare AG |
Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Verhinderung und Behandlung maligner Neoplasien
|
EP1572950B1
(de)
|
2002-06-17 |
2012-10-10 |
Thrasos, Inc. |
Einzeldomäne-tdf-verwandte verbindungen und analoge davon
|
AU2003265556A1
(en)
|
2002-08-20 |
2004-03-11 |
Millenium Pharmaceuticals, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
|
AU2003293013A1
(en)
|
2002-11-21 |
2004-06-18 |
University Of Massachusets |
Diagnosing and treating hematopoietic cancers
|
EP2112229A3
(de)
|
2002-11-25 |
2009-12-02 |
Sequenom, Inc. |
Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
|
WO2004058052A2
(en)
|
2002-12-20 |
2004-07-15 |
Applera Corporation |
Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
|
AU2004206856B9
(en)
*
|
2003-01-16 |
2006-11-02 |
Caprotec Bioanalytics Gmbh |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
JP2007516693A
(ja)
|
2003-06-09 |
2007-06-28 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン |
癌の治療および診断のための組成物および方法
|
EP1668111A4
(de)
|
2003-08-08 |
2008-07-02 |
Genenews Inc |
Osteoarthritis-biomarker und verwendungen davon
|
EP1522594A3
(de)
|
2003-10-06 |
2005-06-22 |
Bayer HealthCare AG |
Verfahren und kit zur untersuchung von krebs
|
KR20060120652A
(ko)
|
2003-10-07 |
2006-11-27 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
난소암의 확인, 평가, 예방 및 치료를 위한 핵산 분자 및단백질
|
CA3050151C
(en)
|
2003-11-26 |
2023-03-07 |
Celera Corporation |
Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
|
CA2852855C
(en)
|
2004-05-07 |
2016-07-05 |
Celera Corporation |
Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
|
US7858323B2
(en)
|
2004-06-09 |
2010-12-28 |
The Regents Of The University Of Michigan |
Phage microarray profiling of the humoral response to disease
|
CA2571218C
(en)
|
2004-06-17 |
2015-11-03 |
William D. Carlson |
Tdf-related compounds and analogs thereof
|
US7459529B2
(en)
|
2004-11-24 |
2008-12-02 |
Seoul National University Industry Foundation |
AIMP2-DX2 and its uses
|
US9944713B2
(en)
|
2004-11-24 |
2018-04-17 |
Medicinal Bioconvergence Research Center |
Antibody specific to the AIMP2-DX2
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
EP1856526A4
(de)
|
2005-01-20 |
2008-11-12 |
Univ Rochester |
Mit thioredoxin interagierendes protein (txnip) als regulator der gefässfunktion
|
CN101495498B
(zh)
|
2005-02-07 |
2013-09-18 |
基因信息公司 |
轻度骨关节炎生物标志物及其用途
|
EP1695981A1
(de)
|
2005-02-25 |
2006-08-30 |
Forschungsverbund Berlin e.V. |
Verfahren zum Redox-Potential-abhängigen Nachweis von Targetmolekülen durch wechselwirkende Polypeptide
|
JP5590697B2
(ja)
|
2005-03-11 |
2014-09-17 |
セレラ コーポレーション |
冠動脈心疾患に関連する遺伝的多型、その検出方法および使用
|
AU2006226861B2
(en)
|
2005-03-22 |
2012-08-16 |
Dana-Farber Cancer Institute, Inc. |
Treatment of protein degradation disorders
|
AU2006236521A1
(en)
|
2005-04-15 |
2006-10-26 |
President And Fellows Of Harvard College |
Methods for modulating bone formation and mineralization by modulating KRC activity
|
JP2008546387A
(ja)
|
2005-06-13 |
2008-12-25 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
癌を処置および診断するための組成物および方法
|
CA2814598A1
(en)
|
2005-09-12 |
2007-03-22 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in prostate cancer
|
US9957569B2
(en)
|
2005-09-12 |
2018-05-01 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in prostate cancer
|
PT2497780E
(pt)
|
2005-09-20 |
2015-08-20 |
Thrasos Innovation Inc |
Compostos relacionados com tdf e seus análogos
|
US7799530B2
(en)
|
2005-09-23 |
2010-09-21 |
Celera Corporation |
Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
|
US8652467B2
(en)
|
2005-10-14 |
2014-02-18 |
The Regents Of The University Of Michigan |
Dek protein compositions and methods of using the same
|
US8239136B2
(en)
|
2005-10-21 |
2012-08-07 |
Genenews Inc. |
Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
JP5368798B2
(ja)
|
2005-10-31 |
2013-12-18 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
癌を診断し処置するための組成物および方法
|
EP2368912B1
(de)
|
2006-01-05 |
2017-05-03 |
Children's Medical Center Corporation |
Regulatoren von NFAT
|
AR059448A1
(es)
|
2006-02-13 |
2008-04-09 |
Divergence Inc |
Polipeptidos quimericos vegetales de union para el reconocimiento molecular universal
|
CA2642273C
(en)
|
2006-02-14 |
2016-09-20 |
President And Fellows Of Harvard College |
Bifunctional histone deacetylase inhibitors
|
JP5497431B2
(ja)
|
2006-05-03 |
2014-05-21 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤
|
US8153369B2
(en)
|
2006-06-05 |
2012-04-10 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
EP2431483B1
(de)
|
2006-10-20 |
2015-04-01 |
Celera Corporation |
Mit venöser Thrombose assoziierte genetische Polymorphismen, Nachweisverfahren und deren Verwendungen
|
DK2447719T3
(en)
|
2007-02-26 |
2016-10-10 |
Oxford Biotherapeutics Ltd |
proteins
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
AU2008222563A1
(en)
|
2007-03-05 |
2008-09-12 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
EP2581081A3
(de)
|
2007-06-01 |
2013-07-31 |
The Trustees Of Princeton University |
Behandlung von Virusinfektionen durch Modulation von Hostzellen-Stoffwechselpfaden
|
HUE027154T2
(en)
|
2007-07-02 |
2016-08-29 |
Oncomed Pharm Inc |
Preparations and procedures for the treatment and diagnosis of cancer
|
AU2008275303B2
(en)
|
2007-07-06 |
2012-05-03 |
The Regents Of The University Of Michigan |
MIPOL1-ETV1 gene rearrangements
|
CA2814246A1
(en)
|
2007-07-06 |
2009-01-15 |
The Regents Of The University Of Michigan |
Solute carrier family 45 member 3 (slc45a3) and erg family gene fusions in prostate cancer
|
WO2009038770A2
(en)
|
2007-09-20 |
2009-03-26 |
University Of Massachusetts Cvip |
Detoxified recombinant botulinum neurotoxin
|
US8039212B2
(en)
|
2007-11-05 |
2011-10-18 |
Celera Corporation |
Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
|
US7892760B2
(en)
|
2007-11-19 |
2011-02-22 |
Celera Corporation |
Lung cancer markers, and uses thereof
|
US20090221620A1
(en)
|
2008-02-20 |
2009-09-03 |
Celera Corporation |
Gentic polymorphisms associated with stroke, methods of detection and uses thereof
|
EP3093351B1
(de)
|
2008-07-09 |
2018-04-18 |
Celera Corporation |
Mit kardiovaskulären krankheiten assoziierte, genetische polymorphismen, verfahren zum nachweis und verwendungen davon
|
JP5665740B2
(ja)
|
2008-07-23 |
2015-02-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
デアセチラーゼ阻害剤およびその使用
|
EP2328908A4
(de)
|
2008-08-28 |
2012-11-28 |
Univ New York State Res Found |
Behandlung von amyloidosen anhand eines myelin-basischen proteins und fragmenten daraus
|
US8962247B2
(en)
|
2008-09-16 |
2015-02-24 |
Sequenom, Inc. |
Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
|
US8476013B2
(en)
|
2008-09-16 |
2013-07-02 |
Sequenom, Inc. |
Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
|
US8551789B2
(en)
|
2010-04-01 |
2013-10-08 |
OncoMed Pharmaceuticals |
Frizzled-binding agents and their use in screening for WNT inhibitors
|
SG190568A1
(en)
|
2008-09-26 |
2013-06-28 |
Oncomed Pharm Inc |
Frizzled-binding agents and uses thereof
|
US9207242B2
(en)
|
2008-10-09 |
2015-12-08 |
The University Of Hong Kong |
Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
|
PL2356462T3
(pl)
|
2008-11-11 |
2017-07-31 |
The Regents Of The University Of Michigan |
Kompozycje anty-CXCR1 oraz sposoby
|
WO2010080985A1
(en)
|
2009-01-08 |
2010-07-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
JP2012514475A
(ja)
|
2009-01-09 |
2012-06-28 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
癌における再現性の遺伝子融合物
|
US20120058131A1
(en)
|
2009-01-21 |
2012-03-08 |
Oxford Biotherapeutics Ltd |
Pta089 protein
|
CA2758322C
(en)
|
2009-04-10 |
2019-04-02 |
Tufts Medical Center, Inc. |
Par-1 activation by metalloproteinase-1 (mmp-1)
|
WO2011019393A2
(en)
|
2009-08-11 |
2011-02-17 |
President And Fellows Of Harvard College |
Class- and isoform-specific hdac inhibitors and uses thereof
|
WO2011034906A2
(en)
|
2009-09-17 |
2011-03-24 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in prostate cancer
|
EP2496605A1
(de)
|
2009-11-02 |
2012-09-12 |
Oxford Biotherapeutics Ltd. |
Ror1 als therapeutisches und diagnostisches ziel
|
US8968740B2
(en)
|
2009-11-13 |
2015-03-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
US20130183326A9
(en)
|
2009-11-20 |
2013-07-18 |
St. Jude Children's Research Hospital |
Methods and compositions for modulating the activity of the interleukin-35 receptor complex
|
EP3660165B1
(de)
|
2009-12-22 |
2023-01-04 |
Sequenom, Inc. |
Verfahren und kits zur identifizierung von aneuploidie
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
WO2011088163A1
(en)
|
2010-01-14 |
2011-07-21 |
President And Fellows Of Harvard College |
Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
|
US10429384B2
(en)
|
2010-01-22 |
2019-10-01 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
|
EP3450979A3
(de)
|
2010-03-17 |
2019-04-24 |
The Regents of The University of Michigan |
Verwendung von phagenepitopen zur profilierung einer immunreaktion
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
EP2552947A4
(de)
|
2010-03-26 |
2013-11-13 |
Dartmouth College |
Vista-regulatorisches t-zellen-mediator-protein, vista-bindende wirkstoffe und verwendung davon
|
US8383793B2
(en)
|
2010-04-15 |
2013-02-26 |
St. Jude Children's Research Hospital |
Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
|
US20110269735A1
(en)
|
2010-04-19 |
2011-11-03 |
Celera Corporation |
Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
|
GB201012420D0
(en)
|
2010-07-23 |
2010-09-08 |
Univ Erasmus Medical Ct |
Foetal heamoglobin inhibitor
|
WO2012051301A1
(en)
|
2010-10-12 |
2012-04-19 |
President And Fellows Of Harvard College |
Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
|
US20120108651A1
(en)
|
2010-11-02 |
2012-05-03 |
Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) |
Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
|
US8945556B2
(en)
|
2010-11-19 |
2015-02-03 |
The Regents Of The University Of Michigan |
RAF gene fusions
|
US9956236B2
(en)
|
2011-02-07 |
2018-05-01 |
Cornell University |
Methods for increasing immune responses using agents that directly bind to and activate IRE-1
|
US20140157443A1
(en)
|
2011-04-14 |
2014-06-05 |
St. Jude Children's Research Hospital |
Methods and compositions for detecting and modulating a novel mtor complex
|
AU2012260601B2
(en)
|
2011-05-25 |
2018-02-01 |
Innate Pharma, S.A. |
Anti-KIR antibodies for the treatment of inflammatory disorders
|
RS55716B1
(sr)
|
2011-06-28 |
2017-07-31 |
Oxford Biotherapeutics Ltd |
Terapeutski i dijagnostički cilj
|
US8969519B2
(en)
|
2011-09-13 |
2015-03-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
ES2716723T3
(es)
|
2011-09-20 |
2019-06-14 |
Univ North Carolina Chapel Hill |
Regulación de los canales de sodio por las proteínas PLUNC
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
ES2640268T3
(es)
|
2012-02-15 |
2017-11-02 |
Novo Nordisk A/S |
Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
|
US9663568B2
(en)
|
2012-02-15 |
2017-05-30 |
Novo Nordisk A/S |
Antibodies that bind peptidoglycan recognition protein 1
|
EP2820129A1
(de)
|
2012-03-02 |
2015-01-07 |
Sequenom, Inc. |
Verfahren und prozesse zur nichtinvasiven beurteilung genetischer variationen
|
EP2825209B1
(de)
|
2012-03-14 |
2018-08-29 |
University of Central Florida Research Foundation, Inc. |
Neurofibromatose-therapeutika und screening dafür
|
US9920361B2
(en)
|
2012-05-21 |
2018-03-20 |
Sequenom, Inc. |
Methods and compositions for analyzing nucleic acid
|
US9730941B2
(en)
|
2012-06-07 |
2017-08-15 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for the inhibition of Pin1
|
AU2013277051B2
(en)
|
2012-06-22 |
2018-06-07 |
King's College London |
Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
US20140093873A1
(en)
|
2012-07-13 |
2014-04-03 |
Sequenom, Inc. |
Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
AU2013312211B2
(en)
|
2012-09-07 |
2018-03-29 |
King's College London |
VISTA modulators for diagnosis and treatment of cancer
|
EP2909341A2
(de)
|
2012-10-18 |
2015-08-26 |
Oslo Universitetssykehus HF |
Biomarker für gebärmutterhalskrebs
|
EP2911691B1
(de)
|
2012-10-23 |
2018-10-10 |
OncoMed Pharmaceuticals, Inc. |
Verfahren zur behandlung von neuroendokrinen tumoren mit wnt-pad-bindemitteln
|
JP2016510411A
(ja)
|
2013-02-04 |
2016-04-07 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Wnt経路インヒビターによる処置の方法およびモニタリング
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP2971100A1
(de)
|
2013-03-13 |
2016-01-20 |
Sequenom, Inc. |
Primer zur analyse der dna-methylierung
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
EP3293275B1
(de)
|
2013-06-06 |
2021-08-04 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzung und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
|
US20160175401A1
(en)
|
2013-07-31 |
2016-06-23 |
Dana-Farber Cancer Institute Inc. |
Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
|
DK3049521T3
(en)
|
2013-09-25 |
2019-04-23 |
Univ Cornell |
Compounds for inducing antitumor immunity and methods thereof
|
WO2015097536A2
(en)
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anti-vista antibodies and fragments
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
EP3736344A1
(de)
|
2014-03-13 |
2020-11-11 |
Sequenom, Inc. |
Verfahren und prozesse zur nichtinvasiven beurteilung genetischer variationen
|
AU2015274504B2
(en)
|
2014-06-11 |
2021-02-04 |
Kathy A. Green |
Use of VISTA agonists and antagonists to suppress or enhance humoral immunity
|
KR20240029114A
(ko)
|
2014-07-17 |
2024-03-05 |
노보 노르디스크 에이/에스 |
점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
|
WO2016011268A1
(en)
|
2014-07-17 |
2016-01-21 |
Beth Israel Deaconess Medical Center, Inc. |
Atra for modulating pin1 activity and stability
|
US10351914B2
(en)
|
2014-07-17 |
2019-07-16 |
Beth Israel Deaconess Medical Center, Inc. |
Biomarkers for Pin1-associated disorders
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
US20160279207A1
(en)
|
2015-03-10 |
2016-09-29 |
University Of Massachusetts |
Targeting gdf6 and bmp signaling for anti-melanoma therapy
|
US10548864B2
(en)
|
2015-03-12 |
2020-02-04 |
Beth Israel Deaconess Medical Center, Inc. |
Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
US20210106661A1
(en)
|
2015-10-29 |
2021-04-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
|
US10899836B2
(en)
|
2016-02-12 |
2021-01-26 |
Janssen Pharmaceutica Nv |
Method of identifying anti-VISTA antibodies
|
WO2017162659A1
(en)
|
2016-03-24 |
2017-09-28 |
Bayer Pharma Aktiengesellschaft |
Intracellular hepsin as therapeutic target for the treatment of cancer with centrosome amplification
|
CA3020848A1
(en)
|
2016-04-15 |
2017-10-19 |
Janssen Pharmaceuticals, Inc. |
Anti-human vista antibodies and use thereof
|
AR117566A1
(es)
|
2018-04-02 |
2021-08-18 |
Bristol Myers Squibb Co |
Anticuerpos anti-trem-1 y sus usos
|